Trials / Conditions / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

11 registered clinical trials studyying B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive A NCT07040982	City of Hope Medical Center	Phase 1
Recruiting	Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia NCT07224100	University of Washington	Phase 2
Recruiting	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma NCT05602194	Children's Oncology Group	Phase 3
Recruiting	Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed NCT04872790	OHSU Knight Cancer Institute	Phase 1
Active Not Recruiting	Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnos NCT04530565	National Cancer Institute (NCI)	Phase 3
Completed	Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia NCT02484430	National Cancer Institute (NCI)	Phase 2
Recruiting	Personalized NK Cell Therapy in CBT NCT02727803	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patient NCT02143414	National Cancer Institute (NCI)	Phase 2
Completed	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and C NCT02311998	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia NCT01424982	M.D. Anderson Cancer Center	Phase 2
Recruiting	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630	M.D. Anderson Cancer Center	Phase 1 / Phase 2